Type 2 (Th2) immune responses play important roles in intestinal immunity by contributing to the maintenance of mucosal homeostasis, not only conferring protection against helminthic infection but also participating in pro-inflammatory pathways in chronic intestinal inflammatory disorders, including inflammatory bowel disease. The current review focuses on recent developments regarding the role of Th2 responses in intestinal inflammation.
INTRODUCTION
Type 2 (Th2) immune responses in the gastrointestinal tract have evolved as a protective mechanism against injury caused by multicellular metazoan parasites of mammals, also known as helminths [1] . Although the 'Th' terminology was, initially, introduced in reference to CD4þ lymphocytic responses, it has now become evident that additional cell populations (of both the innate and adaptive immunity) critically participate in such responses, along with a variety of soluble mediators [2] . The 'core' signature of Th2 responses is the secretion of the cytokines interleukin (IL)-4, IL-15, and IL-13 by lymphocytes that express the transcription factor GATA binding protein 3 (GATA3) [3] . These type 2 cells and modules provide protection from helminthic infections through several additive functions, including smooth muscle hypercontractility, enhanced mucus secretion, and induction of intestinal mastocytosis, all of which aim at worm killing and expulsion. In parallel, Th2 mediators are also involved in the process of wound healing [4] . This combination of protection against infection and tissue repair render Th2 factors critical regulators of intestinal tissue homeostasis. However, when Th2 immunity becomes dysregulated and over-reactive, it may lead to deleterious consequences. On the one hand, the persistence of Th2 effector pathways may lead to unrelenting inflammation, whereas overzealous tissue repair processes may end up in excessive collagen deposition, fibrosis, and stricturing complications. The first pathway is probably involved in the pathogenesis of chronic intestinal inflammation that takes
UPSTREAM REGULATORS OF TYPE 2 IMMUNITY
The initial development of Th2 responses is affected by signals provided by IL-4 itself, but is also regulated by other cytokines. Although the cellular source of the initial burst of IL-4 is not clearly defined, epithelial-derived, Th2-promoting factors have been increasingly delineated. The latter include thymic stromal lymphopoietin (TSLP), IL-25, and IL-33, which are all released after injury to the epithelium and alert the immune system for the breach in epithelial integrity. Among those Th2promoting factors, IL-33 has been the most thoroughly investigated.
IL-33 is a member of the IL-1 family of cytokines, which binds to receptor suppression of tumorigenicity 2 (ST2) [5] . IL-33 localizes to intestinal epithelial cells, and its full-length form is released upon epithelial damage, acting as an 'alarmin' and triggering wound healing at the mucosa [6] . Nevertheless, IL-33 is also capable of inducing inflammation. A recent publication raised the possibility that the final outcome (protection vs. inflammation) may be related to cellular compartmentalization of IL-33 expression. In particular, pro-inflammatory effects were dependent upon loss of nuclear sequestration of IL-33. These pathways were tested in a mouse strain with abolished signal for nuclear localization of IL-33 (IL-33 tm1/þ mice); thus, produced IL-33 was localized to the cytoplasm only [7 & ]. This was associated with constant release of IL-33 into the systemic circulation, which led to a significant increase in serum IL-33 levels. Interestingly, IL-33 tm1/þ mice developed multiorgan inflammation, including enterocolitis, which bore the characteristics of Th2 inflammation, such as eosinophilic infiltration of target tissues and elevated IL-5 expression. When IL-33 tm1/þ were crossed to ST2 null mice, inflammation was abrogated, despite high systemic levels of IL-33. These results imply that IL-33 is sequestrated in the nucleus and this prohibits its systemic release and deleterious pro-inflammatory function. On the contrary, when nuclear sequestration is aborted, IL-33 is released from the cell and induces pro-inflammatory responses, leading to local and systemic inflammation. Whether such a mechanism actually takes place during acute or chronic inflammatory intestinal disorders remains to be elucidated. Irrespective of the specific mechanism, proinflammatory effects of IL-33 were previously shown in experimental models of colitis [8, 9] . In particular, ST2 knockout mice were protected from acute dextran sulphate sodium (DSS) colitis, and administration of anti-ST2 neutralizing antibodies ameliorated the severity of colitis [9] . In a different approach, exogenous IL-33 administration resulted in exaggerated inflammation after DSS administration via the induction of Th2 immunity, with elevations of IL-4 and IL-13 [8] . IL-33 treatment significantly impaired the epithelial barrier integrity and increased intestinal permeability. Furthermore, ST2-deficient mice demonstrated accelerated wound healing after biopsy-inflicted colon injury. Taken together, these studies suggest that IL-33/ST2 signaling may be associated with tissue repair defects, which, at the event of acute trauma, lead to delayed healing and increased leakiness of the gut epithelium, resulting in more severe and prolonged colitis. It should be, however, kept in mind that IL-33 is a Janus-like cytokine that demonstrates dichotomous functions, being either protective or proinflammatory, depending on the specific experimental or clinical conditions [10] . Important recent studies have shown that, apart from its Th2-polarizing effects, IL-33/ST2 signaling plays crucial roles in the development and function of regulatory cell populations at the gut mucosa [11,12 & ]. Regulatory T cells (Tregs) highly express ST2 and respond to alarmin-like IL-33 to restrain intestinal inflammation. Treg responsiveness to IL-33 was enhanced by antigen presenting cell (APC)-derived IL-2 and limited by IL-23 [12 & ]. These results raise the
KEY POINTS
Mucosal Th2 immunity may be initiated via the release of alarmin-type molecules, such as adenosine or IL-33, from injured epithelial cells.
Type II NKT cells that bind lyso-sulfatide glycol lipidloaded CD1d tetramers and secrete IL-13 are a pivotal pathogenic population in ulcerative colitis. Type 2 innate lymphoid cells (ILC2s) are important mediators of mucosal, Th2-type immunity against infection with helminths.
Th2 cytokines are implicated in both pro-inflammatory and homeostatic pathways at the intestinal mucosa.
Neutralization of IL-13 via monoclonal antibodies was ineffective as a therapeutic strategy in patients with ulcerative colitis. possibility that interactions between pro-inflammatory (IL-23-dependent) and regulatory (IL-33dependent) elements dictate the fate of intestinal immune responses [12 & ]. Furthermore, a population of IL-33-induced, IL-10-producing B lymphocytes was recently identified at the intestinal mucosa, which displays the characteristics of a regulatory population with anti-inflammatory properties; hence it was designated as Breg IL-33 cells [13] .
How IL-33 affects the development of Th2 responses in the intestine is not clear. A recent study showed that IL-33 treatment of mucosal lymphocytes led to significant up-regulation of the master Th2 transcription factor GATA3, whereas expression of the Th1 regulator T-box transcription factor T-bet was not affected [14] . In addition, the mucosal expression of IL-33 was significantly elevated and positively correlated with disease severity in two animal models of experimental colitis (piroxicamaccelerated colitis in IL-10 -/mice and DSS colitis) but also in patients with ulcerative colitis. Expression of IL-33 highly correlated with that of GATA3, thus providing indirect evidence for the biological importance of this cytokine as a stimulator of Th2 responses.
Other factors that influence the initial development of Th2 responses were also recently reported in variable systems, with APCs being central to this process. These included negative roles of APCderived IL-6 and of IL-21 on the regulation of Th2 immune responses [15, 16] and a positive role for the subset of CD141þ dendritic cells that preferentially induce the secretion of IL-4 and IL-13 by CD4þ lymphocytes via engagement of the OX40 ligand [17] . Of great importance for intestinal immunity is the recent report that indigenous eosinophils that inhabit the small intestine are capable of inducing Th2-polarizing properties to dendritic cells [18 & ]. It was shown that eosinophil-deficient mice were protected from Th2-mediated peanut food allergy and anaphylaxis. When the eosinophilic pool was reconstituted, protection was aborted. It was subsequently shown that eosinophils critically affected both the activation of CD103þ dendritic cells and their migration to the draining lymph nodes. These were essential steps for Th2 priming of lymphocytes. Control of dendritic cell function was mediated through degranulated eosinophil peroxidase.
DOWNSTREAM EFFECTORS OF TYPE 2 IMMUNITY
Type 2-promoting signals converge to the activation of GATA3, which, in turn, induces transactivation of the IL-4 promoter and up-regulation of IL-5 and IL-13 genes. The importance of GATA3-induced, Th2-cytokine-mediated pathways for the development of intestinal inflammation was clearly shown in a recent study, which examined the severity of DSS-colitis in mice transgenic for T-bet (Th1 dominant), GATA3 (Th2 dominant), and nuclear receptor retinoid-related orphan receptor gt (RORgt) (Th17 dominant) [19] . Interestingly, GATA3 transgenic mice developed the most severe colitis and this was associated with significant mucosal up-regulation of IL-13.
Nowadays, the pool of cells that share the aforementioned properties and fulfill the definition of type 2 effectors has been expanded to include cells other than the CD4þ Th2 subset, with particular attention on type 2 innate lymphoid cells (ILC2s) [20] . These are lineage-negative lymphocytes, lack antigen-specificity, and express markers of Th2polarized cells [21] . They reside at the mucosal sites, including the gut and mesenteric adipose tissue, and are important elements of the defensive response against helminths. Recently, it was shown that during Th2 responses, a cross-talk takes place between ILC2s and CD4þTh2 cells, which is important for optimal antihelminthic responses. In one study, depletion of ILC2s in mice led to impairment of Th2 responses [22 && ]. In this study, ILCs were shown to express major histocompatibility complex class II (MHCII) and bi-directionally interact with Th2 lymphocytes. On the one hand, CD4þ activation by dendritic cells was augmented; on the other hand, T cells secreted IL-2 that subsequently promoted the proliferation of and IL-13 secretion by ILC2s. This was critical for the biological activity of ILCs as deletion of MHCII led to defective expulsion of the helminth Nippostrongylus brasiliensis. These findings were confirmed in another study, which demonstrated that ILC2s and CD4þ T cells positively affect each other's functionality [23] . Similarly to the previous study, CD4þ T cells stimulated ILC2 function by providing IL-2, whereas, ILC2s were capable to express MHCII and present antigens to naive T cells via cell contact both in vitro and in vivo. This interaction favored the development of Th2 immunity, at the same time suppressing Th1 differentiation.
Factors that influence the development and function of ILC2s during protective mucosal immunity are also increasingly recognized. One such factor may be the endogenous danger signal adenosine. It was shown that blockade of adenosine receptor A2BAR negatively affected the development of Th2 responses against the intestinal nematode Heligmosomoides polygyrus and inhibited worm expulsion [24] . In the absence of A2BAR, several parameters of Th2 responses were decreased, including eosinophil recruitment, M2 macrophage infiltration, defective IL-4 and IL-13 production, and compromised IL-33 up-regulation in response to infection. Exogenous IL-33 administration restored effective type 2 immunity. These results showed that when the epithelium is damaged by helminth invasion, several danger-associated molecular patterns (DAMPs) such as IL-33 and adenosine are released and initiate protective immunity at the intestinal mucosa. In a different study, the transcription factor nuclear factor interleukin-3regulated protein (Nfil3) was shown to de required for the development of ILC2s (and ILC3s) [25] . This was of significant biological importance as mice defective for Nfil3 failed to exert effective mucosal responses to C. rodentium infection. ILC2s were also shown to express the tumor necrosis factor (TNF)receptor superfamily member TNFRSF25/DR3 [26 & ]. When DR3 bound to its cognate ligand TNFSF15/ TL1A, augmentation of ILCs development and function was observed. Interestingly, this occurred independently of the presence of IL-25 or IL-33, indicating the presence of redundant pathways for ILC function. Accordingly, mice deficient for DR3 expression failed to clear gut infection by helminths. These studies demonstrate the significance of TL1A/DR3 interactions for mucosal immunity.
The identity of the critical cell population that produces the effector cytokines during pathogenic Th2 immune responses remains undefined. Previous studies showed that, in ulcerative colitis, which is considered a paradigm of Th2 type response, the pathogenetic population is a noninvariant natural killer T (NKT) cell that demonstrates elevated IL-13 production upon stimulation [27] . An important recent study further characterized this population and shed light into the stimulatory triggers for IL-13 production [28 && ]. In particular, cells that are isolated from the lamina propria of ulcerative colitis patients are enriched for type II NKT cells, which are absent in the healthy intestine. These cells are signified by their ability to bind lyso-sulfatide glycol lipid-loaded CD1d tetramer. Upon stimulation, these cells secrete large quantities of IL-13, which denotes a dominance of Th2 responses. They are also capable of inducing epithelial cell cytotoxicity; hence they may contribute to ulcerative colitis pathogenesis via impairment of the epithelial barrier. Interestingly, lyso-sulfatide glycolipid stimulation also led to up-regulation of the receptor IL-13Ra2. Using multicolor quantum dot-staining technology, it was demonstrated that this population is affluent in the lamina propria of ulcerative colitis patients and defined by the concomitant expression of IL-13Ra2 and CD161, and the capability of IL-13 secretion. In all, these findings confirm the predominance of Th2 pathways in ulcerative colitis.
Oxazolone-induced colitis is considered an experimental analog of ulcerative colitis, as both depend on type 2 mucosal immunity. Recently, a novel treatment was tested in oxazolone-treated mice, utilizing a bifunctional IL-4/IL-13 antagonist, in the hope that such combinatorial blockade would overcome the redundant effects of these cytokines [29] . Binding of IL-13 was accomplished via a derivative of the murine IL-13Ra2 extracellular sequence and of IL-4 via a derivative of rat antimouse IL-4 mAb 11B11. Administration of this agent to oxazolone-treated mice was associated with significant amelioration of disease severity. These results are in line with the absence of oxazolone-induced colitis in mice lacking IL-4Ra or STAT6, thus being unable to develop IL-4 or IL-13-mediated immunity [30, 31] .
The aforementioned studies clearly show that Th2 responses may exert pro-inflammatory roles and point out the therapeutic potential of their neutralization. On the contrary, induction of Th2 responses may also be of benefit when mucosal inflammation is mediated through Th1 or Th17 pathways. One such example is the ameliorating effect of IL-4 gene therapy on the severity of 2,4,6-trinitrobenzenesulfonic acid (TNBS) colitis, which is Th1-mediated [32] . Intraperitoneal injection of plasmid pcDNA3.0-mIL-4 resulted in significant decreases in tissue injury by TNBS. This was associated with decreases in the mucosal expression of the interferon (IFN)-g and TNF-a, indicating a suppression of Th1 pro-inflammatory responses. Applying a different approach, Heylen et al. [33] administered soluble worm proteins from Schistosoma mansoni in mice that developed colitis after adoptive transfer of T cells. This model of colitis is Th1/IFN-g-dependent and the pathogenetic hypothesis of worm protein administration was that they would induce an anti-inflammatory Th2 response. Curative (given after the establishment of colitis) and, to a lesser degree, preventive (before colitis establishment) administration of worm proteins resulted in a significant improvement of the clinical and histological parameters of colitis. The immunological effect of such treatment was signified by a decrease in IFN-g and IL-17A mucosal mRNA expression and concomitant elevation of IL-4 expression. Therefore, this potentially Th2-inducing factor modified the mucosal milieu in favor of anti-inflammatory responses. These data are complimentary to the current case for administration of helminths as a therapeutic option in IBD [34, 35] and demonstrate that Th2 responses may be homeostatic or pro-inflammatory at the intestinal mucosa, depending on the specific situation.
THERAPEUTIC IMPLICATIONS
Despite the accumulated evidence pointing to a pivotal role for Th2 immunity during chronic inflammatory pathways at the intestinal mucosa, therapeutic application of anti-IL-13 blockade was associated with highly disappointing results. In the past year, results of large clinical trials reported failure of two anti-IL-13 monoclonal antibodies to induce clinical benefit in patients with moderate to severe ulcerative colitis. In the first study, anrukinzumab, a humanized IgG1, anti-IL-13 antibody, was administered to patients with mild and moderate active ulcerative colitis. Anrukinzumab inhibits attachment of IL-13 to IL-4Ra, without affecting binding to IL-13a1 or IL-13a2 [36 & ]. Treatment with anrukinzumab failed to reach the primary endpoint which was the fold change from baseline in fecal calprotectin at week 14. Secondary outcomes such as change in total Mayo score, clinical response, clinical remission, and mucosal healing also were not met. Similar negative results were reported with tralokinumab (CAT-354), an IL-13-neutralizing human immunoglobulin G4 monoclonal antibody [37 & ]. It was administered in patients with moderate to severe ulcerative colitis. Treatment did not reach statistical significance regarding clinical response, which was the primary endpoint, although there were significant differences in improvements in clinical remission and mean partial Mayo scores between patients who recevied active drug and those who received placebo. The reasons for this quite 'absolute' failure of anti-IL-13 treatment are not easily understood [38] . Accelerated clearance of anrukinzumab was reported in ulcerative colitis patients in comparison to healthy volunteers or patients with asthma [39] . This implies that a suboptimal dose may have been used in the ulcerative colitis trials. Nonetheless, the answer most probably lies in the complexity of immunological pathways that underlie IBD, the wide spectrum of IL-13-mediated effects on mucosal immunity, and the immunophenotype variation within the patient population. Indeed, the high rates of failure of biological therapies should indicate that the model of 'one treatment cures all' must be abandoned and replaced by targeted therapies after careful genetic and immunological phenotyping of patients [40] .
CONCLUSION
In conclusion, Th2 responses are implicated in several aspects of gut homeostasis but also in chronic intestinal inflammation. The latter may be protective as in the case of helminthic infection or deleterious as in IBD. The pathways that mediate these scenarios are constantly enriched with new cellular and molecular components. Better delineation of these mechanisms and understanding of their opposite effects will define the applicability of Th2-targeted therapies for intestinal inflammation.
